Quantum Cyber N.V.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David Elliot Lazar
- Full Time Employees
- 13
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- Robert Koch Strasse 50 Mainz Germany 55129
- IPO Date
- Nov 5, 2021
- CIK
- 0001874252
- Website
- quantum-cyber.ai
- Similar Companies
- Business
- Mainz Biomed N.V. is a molecular diagnostics company focusing on non-invasive screening tests for cancer, with headquarters in Mainz, Germany, and founded in 2008. It develops and commercializes stool- and blood-based diagnostic assays for colorectal cancer and other gastrointestinal diseases, aiming to enable earlier detection and improved patient outcomes; its portfolio includes ColoAlert, a colorectal cancer screening test, and ongoing development programs such as PancAlert for pancreatic cancer, alongside research into additional molecular assays and biomarker-based diagnostics. The company operates primarily in Germany and selected international markets through medical lab partnerships and distribution arrangements, leveraging collaborations with clinical partners and technology providers to expand access to its tests. Mainz Biomed’s business model centers on providing in vitro diagnostic (IVD) products and associated services, including kit development, validation, regulatory compliance support, and partner lab integration, with strategic emphasis on expanding laboratory partnerships, geographic footprint, and product visibility within gastroenterology and oncology screening care pathways. Foundationally, Mainz Biomed maintains its focus on disease-focused molecular diagnostics and targeted disease detection within the gastrointestinal domain, pursuing growth through product line expansion, strategic partnerships, and scale across scientific and clinical collaborations.
Quantum Cyber Completes Acquisition of U.S.-Based Manufacturing Facility in Bridgeport, Connecticut
Quantum Cyber Completes Acquisition of U.S.-Based Manufacturing Facility in Bridgeport, Connecticut
Quantum Cyber Reports Approximately $2 Million of Purchase Orders for Quantum Drone Corporation
Quantum Cyber Files for Drone Launch System Designed to Field Attritable Autonomous Drones at Scale
Quantum Cyber Files for Drone Launch System Designed to Field Attritable Autonomous Drones at Scale
Quantum Cyber Completes Confidential Submission to U.S. Army Program
Quantum Cyber Rejects Short-Seller Claims as it Details Drone Production Plans
Quantum Cyber Targets Annual Production Capacity of 100,000 Drones combining Kamikaze, Interceptor, Surveillance, VTOL and long-range Phantom 950 at Planned Bridgeport, Connecticut Manufacturing Facility
Quantum Cyber Addresses Short Seller Biased Report
Quantum Cyber Introduces PHANTOM-950 Long-Range Autonomous UAS Platform in Development
Quantum Cyber Signs Definitive Agreements to Acquire U.S.-Based Manufacturing Facility in Bridgeport, Connecticut
Quantum Cyber jumps 24% on plans to acquire strategic stake in SpaceX
Quantum Cyber Stock Rises After Board Approves Acquisition of SpaceX Equity Stake
Quantum Cyber Approves Acquisition of Equity Stake in SpaceX
Quantum Cyber Approves Acquisition of Equity Stake in SpaceX
Quantum Cyber Announces Compliance With Trump Administration's National Quantum Initiative Executive Order Following Washington D.C. Delegation and Capitol Hill Engagements
Quantum Cyber Unveils Quantum Station: A Battlefield Operating System for Multi-Domain Autonomous Warfare
Quantum Cyber Issues Letter to Shareholders
Correction: Quantum Cyber Executes Exclusive Quantum Antenna License Agreement, Positoning the Quantum Technology Layer at the Core of Its Defense Platform
Correction: Quantum Cyber Executes Exclusive Quantum Antenna License Agreement, Positoning the Quantum Technology Layer at the Core of Its Defense Platform